Gefapixant
- Generic Name
- Gefapixant
- Brand Names
- Lyfnua
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19N5O4S
- CAS Number
- 1015787-98-0
- Unique Ingredient Identifier
- 6K6L7E3F1L
- Background
It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chroni...
- Indication
用于成人治疗难治性慢性咳嗽（RCC）或不明原因慢性咳嗽（UCC）。
- Associated Conditions
- Refractory Chronic Cough, Unexplained Chronic Cough
- Associated Therapies
- -
Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Stuart Mazzone
- Target Recruit Count
- 31
- Registration Number
- NCT05813223
- Locations
- 🇦🇺
The University of Melbourne, Parkville, Victoria, Australia
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 376
- Registration Number
- NCT04193176
- Locations
- 🇺🇸
Florida Pulmonary Research Institute, LLC ( Site 0008), Winter Park, Florida, United States
🇩🇪Praxis Dr. Wehgartner-Winkler ( Site 0906), Augsburg, Bayern, Germany
🇷🇺Medi Kom ( Site 1456), Saint Petersburg, Sankt-Peterburg, Russian Federation
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 419
- Registration Number
- NCT04193202
- Locations
- 🇬🇹
Clinica Medica Especializada en Neumologia ( Site 0502), Guatemala, Guatemala
🇰🇷Konkuk University Medical Center ( Site 1504), Seoul, Korea, Republic of
🇰🇷Severance Hospital Yonsei University Health System ( Site 1503), Seoul, Korea, Republic of
Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03882801
- Locations
- 🇺🇸
MD Clinical ( Site 0004), Hallandale Beach, Florida, United States
🇺🇸Clinilabs, Inc. ( Site 0005), New York, New York, United States
🇧🇪Universitair Ziekenhuis Gent ( Site 0012), Gent, Belgium
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 175
- Registration Number
- NCT03696108
- Locations
- 🇯🇵
Fukuoka University Chikushi Hospital ( Site 3886), Chikushino, Fukuoka, Japan
🇯🇵National Hospital Organization Nagoya Medical Center ( Site 3898), Nagoya, Aichi, Japan
🇯🇵Nagoya City University Hospital ( Site 3899), Nagoya, Aichi, Japan
A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)
- Conditions
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 187
- Registration Number
- NCT03654326
- Locations
- 🇺🇸
Synexus US Phoenix Southeast ( Site 0729), Chandler, Arizona, United States
🇺🇸Lynn Institute of the Ozarks ( Site 0720), Little Rock, Arkansas, United States
🇺🇸Thameside OBGYN Center ( Site 0747), Groton, Connecticut, United States
Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03569033
- Locations
- 🇬🇧
Hvivo Service Limited. Queen Mary BioEnterprises ( Site 0003), London, United Kingdom
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 732
- Registration Number
- NCT03449134
- Locations
- 🇺🇸
Research Solutions of Arizona PC ( Site 0036), Litchfield Park, Arizona, United States
🇺🇸Medical Research of AZ ( Site 0060), Scottsdale, Arizona, United States
🇦🇷InAER Investigaciones en Alergia y Enfermedades Respiratorias ( Site 0324), Caba, Buenos Aires, Argentina
The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03108924
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 32
- Registration Number
- NCT02790840
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.